Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
2016 · New England Journal of Medicine · 1,957 citations
https://doi.org/10.1056/nejmoa1609709
N
Norbert Marschner
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
328
Papers
7.2K
Citations
33
h-index
70
i10-index
Norbert Marschner is an academic researcher from University Medical Center Freiburg. The author has contributed to research in topics: Advanced Breast Cancer Therapies & Cancer Treatment and Pharmacology & HER2/EGFR in Cancer Research. The author has an h-index of 33, co-authored 279 publications.
ORCID: 0000-0002-6098-1301Papers by this author
worksClinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia
2012 · Annals of Oncology · 109 citations
https://doi.org/10.1093/annonc/mds338
Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer – Results from the prospective German TMK cohort study
2017 · The Breast · 57 citations
https://doi.org/10.1016/j.breast.2017.05.014
Treatment and pattern of bone metastases in 1094 patients with advanced breast cancer – Results from the prospective German Tumour Registry Breast Cancer cohort study
2017 · European Journal of Cancer · 49 citations
https://doi.org/10.1016/j.ejca.2017.03.031
Survival of non-transplant patients with multiple myeloma in routine care differs from that in clinical trials—data from the prospective German Tumour Registry Lymphatic Neoplasms
2018 · Annals of Hematology · 34 citations
https://doi.org/10.1007/s00277-018-3449-8
Quality of life in pre- and postmenopausal patients with early breast cancer: a comprehensive analysis from the prospective MaLife project
2019 · Breast Cancer Research and Treatment · 25 citations
https://doi.org/10.1007/s10549-019-05197-w
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat